Patents by Inventor Emanuela ESPOSITO

Emanuela ESPOSITO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250101491
    Abstract: Method for diagnosing Alzheimer's disease in an individual, comprising the steps of providing at least one serum sample derived from the individual, providing at least one preparation of phage clones expressing peptides that mimic conformational epitopes of the A?-42 peptide, reacting said at least one serum sample with said at least one preparation of phage clones expressing peptides that mimic conformational epitopes of A?-42, so that antibodies that may be present in said serum and are directed against the A?-42 peptide bind to the peptides expressed by phage clones of said preparation of phage clones, detecting, by real-time PCR technique, the quantity of phage clones of said preparation to which said antibodies have bound, and determining, based on the quantity of phage clones of said preparation to which said antibodies have bound, whether the individual from whom said serum sample was derived suffers from Alzheimer's disease.
    Type: Application
    Filed: January 27, 2023
    Publication date: March 27, 2025
    Applicant: UNIVERSITA’ DEGLI STUDI DI MESSINA
    Inventors: Salvatore GUGLIELMINO, Maria Giovanna RIZZO, Domenico FRANCO, Laura Maria DE PLANO, Sabrina CONOCI, Salvatore CUZZOCREA, Emanuela ESPOSITO, Irene PATERNITI, Michela CAMPOLO
  • Patent number: 11633356
    Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: April 25, 2023
    Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.
    Inventors: Anna Rita Blanco, Maria Luisa Bondi', Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Guiseppe Granata, Patrizia Saladino, Clara La Marca, Irene Ceidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
  • Patent number: 11266659
    Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 8, 2022
    Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.
    Inventors: Anna Rita Blanco, Maria Luisa Bondi', Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Giuseppe Granata, Patrizia Saladino, Clara La Marco, Irene Ceidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
  • Patent number: 11253526
    Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: February 22, 2022
    Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.
    Inventors: Anna Rita Blanco, Maria Luisa Bondi′, Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Guiseppe Granata, Patrizia Saladino, Clara La Marca, Irene Deidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
  • Publication number: 20220031614
    Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
    Type: Application
    Filed: August 3, 2020
    Publication date: February 3, 2022
    Inventors: Anna Rita BLANCO, Maria Luisa BONDI', Gennara CAVALLARO, Grazia Maria Letizia CONSOLI, Emanuela Fabiola CRAPARO, Gaetano GIAMMONA, Mariano LICCIARDI, Giovanna PITARRESI, Guiseppe GRANATA, Patrizia SALADINO, Clara LA MARCA, Irene CEIDDA, Salvatore PAPASERGI, Patrizia GUARNERI, Salvatore CUZZOCREA, Emanuela ESPOSITO, Santa VIOLA
  • Publication number: 20210046083
    Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
    Type: Application
    Filed: August 3, 2020
    Publication date: February 18, 2021
    Inventors: Anna Rita BLANCO, Maria Luisa BONDI', Gennara CAVALLARO, Grazia Maria Letizia CONSOLI, Emanuela Fabiola CRAPARO, Gaetano GIAMMONA, Mariano LICCIARDI, Giovanna PITARRESI, Guiseppe GRANATA, Patrizia SALADINO, Clara LA MARCA, Irene CEIDDA, Salvatore PAPASERGI, Patrizia GUARNERI, Salvatore CUZZOCREA, Emanuela ESPOSITO, Santa VIOLA